$GSS cashcow/laggard, Trying to break the TL.Needs a close over 137.5. $HLS is category leader and absolutley flying, whilst GSS can't catch a cold, sorry bid.. until today.
PUMP into the March FDA annoucement?
Next report date
≈
August 28
Report period
H2 2025
EPS estimate
0.03 AUD
Revenue estimate
7.40 M AUD
−0.105 AUD
−17.86 M AUD
9.77 M AUD
164.47 M
About GENETIC SIGNATURES LIMITED
Sector
CEO
Allison Rossiter
Website
Headquarters
Newtown
Founded
2001
ISIN
AU000000GSS4
FIGI
BBG007J39F86
Genetic Signatures Ltd. is a research company, which engages in the identification and commercialization of individual genetic signatures for the diagnosis of infectious diseases. It is also involved in the sale of associated products into the diagnostic and research marketplaces. Its products include the treatment for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. It operates in the following geographical segments: Asia Pacific, Europe, Middle East, and Africa (EMEA), and Americas. The company was founded by Robert J. Birrell, Christopher M. Abbott, and Geoffrey Grigg on February 15, 2001 and is headquartered in Newtown, Australia.
−300%
−240%
−180%
−120%
−60%
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
−16.00 M
−8.00 M
0.00
8.00 M
16.00 M
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−16.00 M
−8.00 M
0.00
8.00 M
16.00 M
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−16.00 M
−8.00 M
0.00
8.00 M
16.00 M
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
−15.00 M
0.00
15.00 M
30.00 M
45.00 M
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
$GSS Quarterly results support the sp. Or is it the other way?ATH close tonight. Seemed to be itchy to break $2 before the close. Looks like Q4 revenue should be a minimum of $5M which is over 200% increase on any other quarter. A growth stock if ever I saw one. See if it follows through tomorrow and then onto who knows where.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GSS is 0.575 AUD — it has increased by 0.88% in the past 24 hours. Watch GENETIC SIGNATURES LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange GENETIC SIGNATURES LIMITED stocks are traded under the ticker GSS.
GSS stock has fallen by −0.86% compared to the previous week, the month change is a 41.98% rise, over the last year GENETIC SIGNATURES LIMITED has showed a −22.82% decrease.
We've gathered analysts' opinions on GENETIC SIGNATURES LIMITED future price: according to them, GSS price has a max estimate of 0.75 AUD and a min estimate of 0.75 AUD. Watch GSS chart and read a more detailed GENETIC SIGNATURES LIMITED stock forecast: see what analysts think of GENETIC SIGNATURES LIMITED and suggest that you do with its stocks.
GSS stock is 0.87% volatile and has beta coefficient of 0.80. Track GENETIC SIGNATURES LIMITED stock price on the chart and check out the list of the most volatile stocks — is GENETIC SIGNATURES LIMITED there?
Today GENETIC SIGNATURES LIMITED has the market capitalization of 130.60 M, it has increased by 15.38% over the last week.
Yes, you can track GENETIC SIGNATURES LIMITED financials in yearly and quarterly reports right on TradingView.
GENETIC SIGNATURES LIMITED is going to release the next earnings report on Aug 28, 2025. Keep track of upcoming events with our Earnings Calendar.
GSS earnings for the last half-year are −0.07 AUD per share, whereas the estimation was 0.00 AUD, resulting in a −1.51 K% surprise. The estimated earnings for the next half-year are 0.03 AUD per share. See more details about GENETIC SIGNATURES LIMITED earnings.
GENETIC SIGNATURES LIMITED revenue for the last half-year amounts to 8.50 M AUD, despite the estimated figure of 8.50 M AUD. In the next half-year revenue is expected to reach 7.40 M AUD.
GSS net income for the last half-year is −15.20 M AUD, while the previous report showed −7.39 M AUD of net income which accounts for −105.60% change. Track more GENETIC SIGNATURES LIMITED financial stats to get the full picture.
No, GSS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENETIC SIGNATURES LIMITED EBITDA is −16.96 M AUD, and current EBITDA margin is −207.07%. See more stats in GENETIC SIGNATURES LIMITED financial statements.
Like other stocks, GSS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENETIC SIGNATURES LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENETIC SIGNATURES LIMITED technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENETIC SIGNATURES LIMITED stock shows the sell signal. See more of GENETIC SIGNATURES LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.